Visa (V) signs a definitive agreement to acquire BioCatch; expected to close by Q2 2027 for deal value at USD 2.4bln

Large-network acquisitions of fraud and authentication specialists fit a well-worn pattern in payments: the card networks have periodically bought risk-scoring, tokenisation and identity capabilities rather than built them, typically at modest size relative to the acquirer, with the strategic logic being that fraud tooling sold across the network's issuer and merchant base compounds transaction volume and justifies take-rate. Deals of this scale rarely move the acquirer's equity beyond the initial session; the historical reaction pattern is a small drift on announcement, with the spread mechanics mattering more for the target, here private, so no arb book is involved. The long dated close, stretching well past a year, is the feature worth noting: extended timelines of this kind usually reflect anticipated regulatory or integration complexity rather than financing, and payments deals have in past episodes drawn antitrust scrutiny in both the US and UK, which sets the cadence of the follow-ons. What typically carries the story forward is the phasing of regulatory filings and any CMA or DOJ engagement, plus whether the target's capabilities get embedded into the network's existing fraud suite, which is where the revenue case historically gets made or lost. For the peer set, acquisitions of fraud-tech assets have tended to prompt similar bolt-ons from the rival network within a cycle or two, so sector read-across is the usual second-order trade.